Supplementary Fig. 5. Follow-up of patients in remission group for 1 year after initial trough levels of infliximab (TLI) measurements. Patients in the remission group were separated into antibodies to infliximab (ATI)-positive (ATI >4.9 µg/mL) and ATI-negative (ATI ≤4.9 µg/mL) groups. The rates of infusion reaction were 17.6% in the ATI-positive group and 2.9% in the ATI-negative group (*P*=0.0967), and the loss of response (LOR) rates after 1 year were 6.7% and 2.9%, respectively (*P*=0.5230), while the proportions in whom TLI had decreased by ≥50.0% were 7.7% and 0%, respectively (*P*=1.0000).